These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 2689017

  • 21. Flow cytometric assessment of clearance and relapse characteristics in psoriasis vulgaris after treatment with weekly clobetasol lotion under hydrocolloid occlusion versus twice-daily clobetasol ointment.
    Glade CP, van der Vleuten CJ, van Erp PE, van de Kerkhof PC.
    Skin Pharmacol Appl Skin Physiol; 2002; 15(2):92-9. PubMed ID: 11867965
    [Abstract] [Full Text] [Related]

  • 22. A clinical and flow cytometric model to study remission and relapse in psoriasis.
    Glade CP, van Erp PE, Werner-Schlenzka H, van de Kerkhof PC.
    Acta Derm Venereol; 1998 May; 78(3):180-5. PubMed ID: 9602222
    [Abstract] [Full Text] [Related]

  • 23. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis.
    Nielsen PG.
    Acta Derm Venereol; 1993 Oct; 73(5):394. PubMed ID: 7904413
    [No Abstract] [Full Text] [Related]

  • 24. Intermittent treatment of psoriasis with clobetasol propionate.
    Hradil E, Lindström C, Möller H.
    Acta Derm Venereol; 1978 Oct; 58(4):375-7. PubMed ID: 82342
    [Abstract] [Full Text] [Related]

  • 25. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
    Decroix J, Pres H, Tsankov N, Poncet M, Arsonnaud S.
    Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
    [Abstract] [Full Text] [Related]

  • 26. A comparison of clobetasol propionate 0.05 percent ointment and an optimized betamethasone dipropionate 0.05 percent ointment in the treatment of psoriasis.
    Jacobson C, Cornell RC, Savin RC.
    Cutis; 1986 Mar; 37(3):213-4, 216, 218-20. PubMed ID: 3514155
    [Abstract] [Full Text] [Related]

  • 27. The effect on psoriasis of clobetasol propionate used alone or in combination with UVB.
    Larkö O, Swanbeck G, Svartholm H.
    Acta Derm Venereol; 1984 Mar; 64(2):151-4. PubMed ID: 6203304
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Effect of an anthralin-containing hydrocolloid dressing in psoriasis vulgaris].
    Bunse T, Merk H.
    Z Hautkr; 1990 Aug; 65(8):730-2. PubMed ID: 2284832
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
    Menter MA, Caveney SW, Gottschalk RW.
    J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
    [Abstract] [Full Text] [Related]

  • 32. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation.
    Duteil L, Queille C, Poncet M, Ortonne JP, Czernielewski J.
    Clin Exp Dermatol; 1990 May; 15(3):195-9. PubMed ID: 2364573
    [Abstract] [Full Text] [Related]

  • 33. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
    Lee CS, Koo J.
    J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
    [Abstract] [Full Text] [Related]

  • 34. The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol 17-propionate in vivo.
    Watson WS, Finlay AY.
    Br J Dermatol; 1988 Apr; 118(4):523-30. PubMed ID: 3377973
    [Abstract] [Full Text] [Related]

  • 35. [Effective treatment of chronic inflammatory skin diseases. Once a week occlusion therapy with clobetasol propionate and Duoderm].
    Volden G.
    Tidsskr Nor Laegeforen; 1992 Apr 10; 112(10):1272-4. PubMed ID: 1579907
    [Abstract] [Full Text] [Related]

  • 36. Superpotent topical steroid treatment of psoriasis vulgaris--clinical efficacy and adrenal function.
    Katz HI, Hien NT, Prawer SE, Mastbaum LI, Mooney JJ, Samson CR.
    J Am Acad Dermatol; 1987 Apr 10; 16(4):804-11. PubMed ID: 3553247
    [Abstract] [Full Text] [Related]

  • 37. A Comparative Study to Evaluate Epidermal Barrier Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus Betamethasone Dipropionate 0.05% Lotion.
    Hashim PW, Nia JK, Terrano D, Goldenberg G, Kircik LH.
    J Drugs Dermatol; 2017 Aug 01; 16(8):747-752. PubMed ID: 28809989
    [Abstract] [Full Text] [Related]

  • 38. Occlusive hydrocolloid dressings decrease keratinocyte population growth fraction and clinical scale and skin thickness in active psoriatic plaques.
    Gottlieb AB, Staiano-Coico L, Cohen SR, Varghese M, Carter DM.
    J Dermatol Sci; 1990 Mar 01; 1(2):93-6. PubMed ID: 1713058
    [Abstract] [Full Text] [Related]

  • 39. [Comparative study of clobetasol 17-propionate and traimcinolone acetonide].
    Esser B.
    Z Hautkr; 1979 Oct 15; 54(20):893-7. PubMed ID: 392970
    [No Abstract] [Full Text] [Related]

  • 40. Non-invasive evaluation of topical calcipotriol versus clobetasol in the treatment of psoriasis.
    Berardesca E, Vignoli GP, Farinelli N, Vignini M, Distante F, Rabbiosi G.
    Acta Derm Venereol; 1994 Jul 15; 74(4):302-4. PubMed ID: 7976093
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.